Quality of life in multiple sclerosis: Effects of current treatment options

References

• Alshubaili AF, Awadalla AW, Ohaeri JU, Mabrouk AA. Relationship of depression, disability, and family caregiver attitudes to the quality of life of Kuwaiti persons with multiple sclerosis: A controlled study. BioMedCentral Neurology 2007; 7: 31
   PubMed Web of Science ®Google Scholar
• Alshubaili AF, Ohaeri JU, Awadalla AW, Mabrouk AA. Quality of life in multiple sclerosis: A Kuwaiti MSQOL-54 experience. Acta Neurologica Scandinavica 2008; 117: 384–392
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Archives of Neurology 1995; 52: 168–172
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Archives of Neurology 2001; 58: 1602–1606
   PubMed Web of Science ®Google Scholar
• Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Multiple Sclerosis 2000; 6: 338–432
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Baier ML, Kunkle AM, Rudick RA, Weinstock-Guttman B, Simonian N, et al. Self-reported visual dysfunction in multiple sclerosis: Results from the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). Multiple Sclerosis 2000; 6: 382–385
   PubMedGoogle Scholar
• Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. European Neurology 2002; 47: 11–14
   PubMed Web of Science ®Google Scholar
• Basso MR, Lowery N, Ghormley C, Combs D, Johnson J. Self-generated learning in people with multiple sclerosis. Journal of the International Neuropsychological Society 2006; 12: 640–648
   PubMed Web of Science ®Google Scholar
• Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, et al. Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis 2007; 13: 386–392
   PubMed Web of Science ®Google Scholar
• Benedict RH, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. Journal of Neuroimaging 2004; 14: 36S–45S
   PubMed Web of Science ®Google Scholar
• Bethoux F, Miller DM, Kinkel RP. Recovery following acute exacerbations of multiple sclerosis: From impairment to quality of life. Multiple Sclerosis 2001; 7: 137–142
   PubMed Web of Science ®Google Scholar
• Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: A review of recent developments. Current Opinion in Neurology 2003; 16: 283–288
   PubMed Web of Science ®Google Scholar
• Brenk A, Laun K, Haase CG. Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis. European Neurology 2008; 60: 304–309
   PubMed Web of Science ®Google Scholar
• Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Multiple Sclerosis 2003; 9: 458–460
   PubMed Web of Science ®Google Scholar
• Brochet B, Deloire MS, Ouallet JC, Salort E, Bonnet M, Jové J, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: A two-year longitudinal study. The Clinical Journal of Pain 2009; 25: 211–217
   PubMed Web of Science ®Google Scholar
• Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of corticosteroids on short-term and long-term memory. Neurology 2005; 64: 335–337
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. The Lancet Neurology 2009; 8: 244–253
   PubMed Web of Science ®Google Scholar
• Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129–139
   PubMed Web of Science ®Google Scholar
• Chia YW, Fowler CJ, Kamm MA, Henry MM, Lemieux MC, Swash M. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. Journal of Neurology 1995; 242: 105–108
   PubMed Web of Science ®Google Scholar
• Clark CM, Fleming JA, Li D, Oger J, Klonoff H, Paty D. Sleep disturbance, depression, and lesion site in patients with multiple sclerosis. Archives of Neurology 1992; 49: 641–643
   PubMedGoogle Scholar
• Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Archives of Neurology 2001; 58: 961–967
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–687
   PubMed Web of Science ®Google Scholar
• Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008; 71: S3–7
   PubMed Web of Science ®Google Scholar
• Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: A multimodal approach. Clinical Therapeutics 2006; 28: 445–460
   PubMed Web of Science ®Google Scholar
• Decoo D, on behalf of the MS Rehab Study Group. Effects of donepezil in multiple sclerosis. Multiple Sclerosis 2004; 10: S150
   Google Scholar
• D’Intino G, Paradisi M, Fernandez M, Giuliani A, Aloe L, Giardino L, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proceedings of the National Academy of Sciences USA 2005; 102: 3070–3075
   PubMed Web of Science ®Google Scholar
• Doraiswamy PM, Rao SM. Treating cognitive deficits in multiple sclerosis: Are we there yet?. Neurology 2004; 63: 1552–1553
   PubMedGoogle Scholar
• Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH. Chronic pain in a large community sample of persons with multiple sclerosis. Multiple Sclerosis 2003; 9: 605–611
   PubMed Web of Science ®Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497
   PubMed Web of Science ®Google Scholar
• Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999; 5: 251–259
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Annals of Neurology 2000; 48: 885–892
   PubMed Web of Science ®Google Scholar
• Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery & Psychiatry 2005; 76: 58–63
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: Better outcomes for patients and society?. Drugs 2003; 63: 1525–1533
   PubMedGoogle Scholar
• Flechter S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: An open-label prospective one year study. Journal of Israel Medical Association 2007; 9: 457–459
   PubMed Web of Science ®Google Scholar
• Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: A multidisciplinary approach to evaluation and management. Nature Clinical Practice Urology 2009; 6: 96–107
   PubMedGoogle Scholar
• Foley FW, Dince WM, Bedell JR, La Rocca NG, Kalb R, Caruso LS, et al. Psychoremediation of communication skills for cognitively impaired persons with multiple sclerosis. Journal of NeuroEngineering and Rehabilitation 1994; 8: 165–176
   Google Scholar
• Foster HE, Jr. Bladder symptoms and multiple sclerosis. Muir Scler Quart Rep 2002; 21: 5–8
   Google Scholar
• Freal JE, Kraft GH, Coryell JK. Multiple sclerosis patients’ assessment of their medical, psychological, social, and vocational needs. Archives of Physical Medicine and Rehabilitation 1980; 61: 487
   Google Scholar
• Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, et al. Interferon-beta1b in the treatment of secondary progressive MS: Impact on quality of life. Neurology 2001; 57: 1870–1875
   PubMed Web of Science ®Google Scholar
• Gentry T. PDAs as cognitive aids for people with multiple sclerosis. American Journal of Occupational Therapy 2008; 62: 18–27
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909–913
   PubMed Web of Science ®Google Scholar
• Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 1332–1338
   PubMed Web of Science ®Google Scholar
• Hadjimichael O, Vollmer T, Oleen-Burkey M, North American Research Committee on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: The North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health and Quality of Life Outcomes 2008; 6: 100
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–2025
   PubMed Web of Science ®Google Scholar
• Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis?. Quarterly Journal of Medicine 2004; 97: 671–676
   Google Scholar
• Henze T. Managing specific symptoms in people with multiple sclerosis. The International MS Journal 2005; 12: 60–68
   PubMedGoogle Scholar
• Hildebrandt H, Lanz M, Hahn HK, Hoffmann E, Schwarze B, Schwendemann G, et al. Cognitive training in MS: Effects and relation to brain atrophy. Restorative Neurology and Neuroscience 2007; 25: 33–43
   PubMed Web of Science ®Google Scholar
• Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 1990; 98: 1538–1542
   PubMed Web of Science ®Google Scholar
• Hohol MJ, Guttmann CR, Orav J, Mackin GA, Kikinis R, Khoury SJ, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Archives of Neurology 1997; 54: 1018–1025
   PubMedGoogle Scholar
• Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology 2009; 256: 405–415
   PubMed Web of Science ®Google Scholar
• Italian REMS Study Group, Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: The REMS study. Sleep 2008; 31: 944–952
   PubMedGoogle Scholar
• Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology 1996; 39: 285–294
   PubMed Web of Science ®Google Scholar
• Janardhan V, Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Archives of Neurology 2000; 57: 1485–1491
   PubMed Web of Science ®Google Scholar
• Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. Journal of the Neurological Sciences 2002; 205: 51–58
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268–1276
   PubMed Web of Science ®Google Scholar
• Jønsson A, Korfitzen EM, Heltberg A, Ravnborg MH, Byskov-Ottosen E. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurologica Scandinavica 1993; 88: 394–400
   PubMed Web of Science ®Google Scholar
• José Sá M. Psychological aspects of multiple sclerosis. Clinical Neurology and Neurosurgery 2008; 110: 868–877
   PubMed Web of Science ®Google Scholar
• Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Multiple Sclerosis 2004; 10: S46–S54
   Google Scholar
• Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57: 1969–1975
   PubMed Web of Science ®Google Scholar
• Kern S, Schrempf W, Schneider H, Schultheiss T, Reichmann H, Ziemssen T. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Multiple Sclerosis 2009; 15: 752–758
   PubMed Web of Science ®Google Scholar
• Khan F, Pallant JF, Brand C, Kilpatrick TJ. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: A randomised controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 2008; 79: 1230–1235
   PubMed Web of Science ®Google Scholar
• Kroencke DC, Lynch SG, Denney DR. Fatigue in multiple sclerosis: Relationship to depression, disability, and disease pattern. Multiple Sclerosis 2000; 6: 131–136
   PubMed Web of Science ®Google Scholar
• Krokavcova M, van Dijk JP, Nagyova I, Rosenberger J, Gavelova M, Gdovinova Z, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: A review. Scandinavian Journal of Caring Sciences 2009; 23: 529–538
   PubMed Web of Science ®Google Scholar
• Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Archives of Neurology 1988; 45: 435–437
   PubMed Web of Science ®Google Scholar
• Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis 2006; 12: 321–324
   PubMedGoogle Scholar
• Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: The effect of disease modifying treatment. Multiple Sclerosis 2006; 12: 808–813
   PubMedGoogle Scholar
• Lincoln NB, Dent A, Harding J, Weyman N, Nicholl C, Blumhardt LD, et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2002; 72: 93–98
   PubMed Web of Science ®Google Scholar
• Lyros E, Messinis L, Papageorgiou S, Papathanasopoulos P. Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions. International Review of Psychiatry, 22: 35–42
   PubMedGoogle Scholar
• Manconi M, Fabbrini M, Bonanni E, Filippi M, Rocca M, Murri L, et al. High prevalence of restless legs syndrome in multiple sclerosis. European Journal of Neurolog 2007; 14: 534–539
   PubMed Web of Science ®Google Scholar
• Mattson D, Petrie M, Srivastava DK, McDermott M. Multiple sclerosis. Sexual dysfunction and its response to medications. Archieves of Neurology 1995; 52: 862–868
   PubMed Web of Science ®Google Scholar
• Merkelbach S, Sittinger H, Koenig J. Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis?. The Journal of Nervous and Mental Disease 2002; 190: 388–393
   PubMed Web of Science ®Google Scholar
• Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: Relationship to patient-reported quality of life. Archives of Neurology 2000; 57: 1319–1324
   PubMed Web of Science ®Google Scholar
• Miller DM, Rudick RA, Baier M, Cutter G, Dougherty DS, Weinstock-Guttman B, et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 2003; 9: 1–5
   PubMedGoogle Scholar
• Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Multiple Sclerosis 2002; 8: 161–168
   PubMed Web of Science ®Google Scholar
• Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72: 1760–1765
   PubMedGoogle Scholar
• Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000; 55: 51–54
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica 1998; 97: 366–369
   PubMedGoogle Scholar
• Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. Journal of the Neurological Sciences 2004; 218: 3–7
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM. Hopelessness ratings in relapsing-remitting and secondary progressive multiple sclerosis. International Journal of Psychiatry in Medicine 2002; 32: 155–165
   PubMed Web of Science ®Google Scholar
• Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F, et al. Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients – A randomised controlled trial. Journal of Neurology 2003; 250: 861–866
   PubMed Web of Science ®Google Scholar
• Patti F, Pozzilli C, Montanari E, Pappalardo A, Piazza L, Levi A, et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Multiple Sclerosis 2007; 13: 783–791
   PubMed Web of Science ®Google Scholar
• Pierson SH, Griffith N. Treatment of cognitive impairment in multiple sclerosis. Behavioral Neurology 2006; 17: 53–67
   PubMed Web of Science ®Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47: 1463–1468
   PubMed Web of Science ®Google Scholar
• Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22: 291–324
   PubMed Web of Science ®Google Scholar
• Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. Journal of the Neurological Sciences 2006; 245: 177–181
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1996; 352: 1498–1504
   Google Scholar
• Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, et al. Quality of life in 1,000 patients with early relapsing-remitting multiple sclerosis. European Journal of Neurology 2009; 16: 713–720
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685–691
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692–696
   PubMed Web of Science ®Google Scholar
• Rice GP, Oger J, Duquette P, Francis GS, Bélanger M, Laplante S, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. The Canadian Journal of Neurological Sciences 1999; 26: 276–282
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Traboulsee A, Devonshire V, Oger J. Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Diseases 2008; 1: 181–192
   PubMedGoogle Scholar
• Ritvo PG, Fisher JS, Miller DM, Andrews H, Paty DW, Larocca NG. Multiple Sclerosis Quality of Life Inventory (MSQLI): A user's manual. National Multiple Sclerosis Society, New York 1997
   Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis 2004; 10: 589–595
   PubMedGoogle Scholar
• Robinson D, Jr, Zhao N, Gathany T, Kim LL, Cella D, Revicki D. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: Baseline data from an international clinical trial. Current Medical Research and Opinion 2009; 25: 1121–1130
   PubMed Web of Science ®Google Scholar
• Romberg A, Virtanen A, Ruutiainen J, Aunola S, Karppi SL, Vaara M, et al. Effects of a six-month exercise program on patients with multiple sclerosis: A randomized study. Neurology 2004; 63: 2034–2038
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56: 1324–1330
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: Current evidence, measurement and effects of disease severity and treatment. CNS Drugs 2008; 22: 827–839
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health-related quality of life in multiple sclerosis: Effects of natalizumab. Annals of Neurology 2007; 62: 335–346
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628–632
   PubMed Web of Science ®Google Scholar
• Scarrabelotti M, Carroll M. Memory dissociation and metamemory in multiple sclerosis. Neuropsychologia 1999; 37: 1335–1350
   PubMed Web of Science ®Google Scholar
• Schapiro RT. Pharmacologic options for the management of multiple sclerosis symptoms. Neurorehabilitation and Neural Repair 2002; 16: 223–231
   PubMedGoogle Scholar
• Schultheis MT, Garay E, DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 2001; 56: 1089–1094
   PubMed Web of Science ®Google Scholar
• Schwarz S, Leweling H. Multiple sclerosis and nutrition. Multiple Sclerosis 2005; 11: 24–32
   PubMed Web of Science ®Google Scholar
• Scott LJ, Figgitt DP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs 2004; 18: 379–396
   PubMed Web of Science ®Google Scholar
• Selby MJ, Ling N, Williams JM, Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Perceptual and Motor Skills 1998; 86: 1099–1106
   PubMedGoogle Scholar
• Shevil E, Finlayson M. Process evaluation of a self-management cognitive program for persons with multiple sclerosis. Patient Education and Counseling 2009; 76: 77–83
   PubMed Web of Science ®Google Scholar
• Siegert RJ, Abernethy DA. Depression in multiple sclerosis: A review. Journal of Neurology Neurosurg Psychiatry 2005; 76: 469–475
   PubMed Web of Science ®Google Scholar
• Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health and Quality of Life Outcomes 2006; 4: 96
   PubMed Web of Science ®Google Scholar
• Slater RJ, LaRocca NG, Scheinberg LC. Development and testing of a minimal record of disability in multiple sclerosis. Annals of the New York Academy of Sciences 1984; 436: 453–468
   PubMedGoogle Scholar
• Sohlberg MM, Mateer CA. Cognitive rehabilitation: An integrative neuropsychological approach. Guilford Press, New York 2001
   Google Scholar
• Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D’Aleo G, et al. The prevalence of pain in multiple sclerosis: A multicenter cross-sectional study. Neurology 2004; 63: 919–921
   PubMed Web of Science ®Google Scholar
• Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. alpha4-Integrin antagonism with natalizumab: Effects and adverse effects. Journal of Neurology 2008; 255: 58–65
   PubMed Web of Science ®Google Scholar
• Tesar N, Baumhackl U, Kopp M, Günther V. Effects of psychological group therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica 2003; 107: 394–399
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–1285
   PubMed Web of Science ®Google Scholar
• Thompson AJ. Neurorehabilitation in multiple sclerosis: Foundations, facts and fiction. Current Opinion in Neurology 2005; 18: 267–271
   PubMedGoogle Scholar
• Tumani H, Uttner I. Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis. Journal of Neurology 2007; 254: II69–72
   PubMedGoogle Scholar
• Turner AP, Kivlahan DR, Haselkorn JK. Exercise and quality of life among people with multiple sclerosis: Looking beyond physical functioning to mental health and participation in life. Archives of Physical Medicine and Rehabilitation 2009; 90: 420–428
   PubMed Web of Science ®Google Scholar
• Uttner I, Müller S, Zinser C, Maier M, Süssmuth S, Claus A, et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005; 64: 1971–1973
   PubMedGoogle Scholar
• Vanage SM, Gilbertson KK, Mathiowetz V. Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. American Journal of Occupational Therapy 2003; 57: 315–323
   PubMed Web of Science ®Google Scholar
• Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: Influence of interferon-beta1 a (Avonex) treatment. Multiple Sclerosis 2002; 8: 377–381
   PubMed Web of Science ®Google Scholar
• Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. Journal of Clinical Epidemiology 1997; 50: 557–569
   PubMed Web of Science ®Google Scholar
• Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of life Research 1995; 4: 187–206
   PubMed Web of Science ®Google Scholar
• Visschedijk MA, Uitdehaag BM, Klein M, van der Ploeg E, Collette EH, Vleugels L, et al. Value of health-related quality of life to predict disability course in multiple sclerosis. Neurology 2004; 63: 2046–2050
   PubMed Web of Science ®Google Scholar
• Vogt A, Kappos L, Calabrese P, Stöcklin M, Gschwind L, Opwis K, et al. Working memory training in patients with multiple sclerosis – Comparison of two different training schedules. Restorative Neurology and Neuroscience 2009; 27: 225–235
   PubMed Web of Science ®Google Scholar
• Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Archives of Neurology 1999; 56: 319–324
   PubMed Web of Science ®Google Scholar
• White LJ, McCoy SC, Castellano V, Gutierrez G, Stevens JE, Walter GA, et al. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Multiple Sclerosis 2004; 10: 668–674
   PubMed Web of Science ®Google Scholar
• Wynia K, Middel B, van Dijk JP, De Keyser JH, Reijneveld SA. The impact of disabilities on quality of life in people with multiple sclerosis. Multiple Sclerosis 2008; 14: 972–980
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. The New England Journal of Medicine 2006; 354: 924–933
   PubMed Web of Science ®Google Scholar
• Ziemssen T. Multiple sclerosis beyond EDSS: Depression and fatigue. Journal of the Neurological Sciences 2009; 277: S37–41
   Google Scholar
• Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences 2003; 216: 113–118
   PubMed Web of Science ®Google Scholar